The overall goal of the University of lowa/Mayo Clinic Lymphoma SPORE (UI/MC SPORE) Administration Core is to stimulate research in lymphoma and to expedite the translation of discoveries into new and better methods of prevention, detection, and treatment of lymphoma. The Administration Core has served well as the organizational hub of UI/MC SPORE during the prior funding periods. During the next grant period (years 11-15), it will continue to provide an organizational structure designed to coordinate the activities ofthe research projects, scientific ceres, and developmental programs (Developmental Research Program, Career Development Program) at both institutions. The Administration Core will be responsible for coordinating the function of the SPORE committees including the Executive Committee and the External Advisory Committee, Dr. George Weiner will serve as Director of the Administration Core, and Dr. Thomas Witzig as Co- Director. Weiner and Witzig functioned well as a team during the prior funding periods, and will continue to work collaboratively to provide oversight of SPORE activities. The Administration Core will 1) Provide leadership, organizational support, and financial management for UI/MC SPORE investigators;2) Coordinate communication and collaboration between lowa and Mayo, including support for exchange of ideas between investigators, design of new projects, conduct of translational research, and reporting of translational research findings;3) Provide information transfer to the scientific community and the public;4) Provide leadership and organizational support for internal and external review for UI/MC SPORE research projects;5) Provide the structure for the establishment and nurture of collaborations to facilitate and expand lymphoma research including interactions between lowa and Mayo;6) Work closely with SPORE patient advocates se that they are aware of the progress of the SPORE, and facilitate their ability to provide input at all levels;7) Foster trainee development;8) Communicate with the NCI.

Public Health Relevance

The Administration Cere provides administrative support for all UI/MC SPORE research activities and assures there is excellent communication between lowa and Mayo, and all participating investigators and staff. The Administration Core also assures that patient advocates participate in videoconferences and annual retreats and are included in all key decisions. It is a necessary component for a successful SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097274-12
Application #
8561358
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
12
Fiscal Year
2013
Total Cost
$130,202
Indirect Cost
$23,436
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Thanarajasingam, Gita; Maurer, Matthew J; Farooq, Umar et al. (2018) Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. Br J Haematol 183:149-152
Kleinstern, Geffen; Maurer, Matthew J; Liebow, Mark et al. (2018) History of autoimmune conditions and lymphoma prognosis. Blood Cancer J 8:73
Saad Aldin, Ehab; McNeely, Parren; Menda, Yusuf (2018) Posterior Reversible Encephalopathy Syndrome on 18F-FDG PET/CT in a Pediatric Patient With Burkitt's Lymphoma. Clin Nucl Med 43:195-198
Link, Brian K; Day, Bann-Mo; Zhou, Xiaolei et al. (2018) Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol :
Ebeid, Kareem; Meng, Xiangbing; Thiel, Kristina W et al. (2018) Synthetically lethal nanoparticles for treatment of endometrial cancer. Nat Nanotechnol 13:72-81
Holahan, Heather M; Farah, Ronda S; Fitz, Sara et al. (2018) Health-related quality of life in patients with cutaneous T-cell lymphoma? Int J Dermatol 57:1314-1319
Maurer, Matthew J; Ghesquières, Hervé; Link, Brian K et al. (2018) Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. J Clin Oncol 36:1603-1610
Huet, Sarah; Tesson, Bruno; Jais, Jean-Philippe et al. (2018) A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol 19:549-561
El-Galaly, Tarec Christoffer; Cheah, Chan Yoon; Bendtsen, Mette Dahl et al. (2018) Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer 93:57-68
Mackrides, Nicholas; Chapman, Jennifer; Larson, Melissa C et al. (2018) Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma. Am J Hematol :

Showing the most recent 10 out of 387 publications